CJC-1295 (No DAC) vs CJC-1295 with DAC

Written by the Pure Peptides editorial team

Reviewed by Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer · Reviewed

Published · Updated · 9 references

CJC-1295 (No DAC) and CJC-1295 with DAC are two different molecules: CJC-1295 with DAC is a chemically modified form carrying an albumin-binding group that CJC-1295 (No DAC) lacks.

CJC-1295 (No DAC)

CJC-1295 (No DAC)

View CJC-1295 (No DAC)
vs
CJC-1295 with DAC

CJC-1295 with DAC

View CJC-1295 with DAC

Structure at a glance

CJC-1295 (No DAC) corresponds to residues 1 to 29 of CJC-1295 with DAC.

CJC-1295 with DAC · 30 residues

NH2

CJC-1295 (No DAC) · 29 residues

NH2: C-terminal amide. A raised D marks a D-amino acid. Lys*: Lys carrying a maleimidopropionyl group. Codes are three-letter amino acid codes.

Chain length
CJC-1295 (No DAC)29 residues
CJC-1295 with DAC30 residues
Molecular weight
CJC-1295 (No DAC)3,367.97 g/mol
CJC-1295 with DAC3,647.28 g/mol

Drawn from the product database. Each measure's bars share one scale.

CJC-1295 (No DAC) vs CJC-1295 with DAC, compared
What it isA synthetic analog of growth hormone-releasing hormone. Built on the GRF(1-29) backbone, with four amino acid substitutions.[1]The same substituted GRF(1-29) backbone, with an added group that reacts with a free thiol on albumin.[1]
How they relateCJC-1295 with DAC is a chemically modified form of CJC-1295 (No DAC). The added group binds covalently to albumin.[1]
CAS number446036-97-1446262-90-4
Molecular formulaC152H252N44O42C165H269N47O46
Molecular weight3,367.97 g/mol3,647.28 g/mol
SequenceTyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(maleimidopropionyl)-NH2
TargetThe GHRH receptor, a class B G protein-coupled receptor on anterior pituitary somatotrophs.The same GHRH receptor. Its albumin conjugate stimulated growth hormone release from cultured rat pituitary cells, and given to rats it raised plasma growth hormone.[1]
Reported half-lifeEssentially uncharacterized in humans.[2]Estimated half-life 5.8 to 8.1 days, in healthy volunteers.[3][4]
Evidence baseIn the literature reviewed for CJC-1295 (No DAC), the pharmacokinetic findings were generated with the DAC form. Essentially uncharacterized in humans.[2]Three published human studies, in 63 healthy volunteers.[4] The third analyzed a subset of the second cohort, not an independent third group.[5][4] Independent replication is limited. They were not designed to test a clinical endpoint.
Regulatory statusNo approved product in the United States, the European Union or 12 other countries FDA checked.[4]No approved product in the United States, the European Union or 12 other countries FDA checked.[4]
Compared head-to-head?No direct comparison found in PubMed (searched October 2026).[6]
Handling differenceNeither molecule contains sulfur, so no disulfide chemistry applies to either. The bond attaching the group on CJC-1295 with DAC can hydrolyze, leaving two separate species.
Where they get confusedJette and colleagues identified the albumin-binding conjugate as CJC-1295.[1] A widely circulated CAS number for that conjugate resolves instead to the DAC-free peptide. That peptide is also sold as Modified GRF(1-29).

How CJC-1295 (No DAC) and CJC-1295 with DAC differ

CJC-1295 (No DAC) and CJC-1295 with DAC are not the same molecule. Both are built on the same substituted GRF(1-29) backbone.[1] CJC-1295 with DAC also carries an added group that reacts with a free thiol on albumin.[1] The core sold as CJC-1295 (No DAC) lacks that group. Jette and colleagues identified the albumin-binding conjugate under the name CJC-1295, in work in rats.[1]

In the literature reviewed for CJC-1295 with DAC, every figure was obtained with the DAC form alone, and CJC-1295 (No DAC) is essentially uncharacterized in humans.[2] In the literature reviewed for CJC-1295 (No DAC), the pharmacokinetic findings were generated with the DAC form as well. Much of that DAC-form work is preclinical, and independent replication is limited. The literature reviewed for CJC-1295 (No DAC) reports no human safety data for CJC-1295 (No DAC) itself.

The human record for the DAC form is three published studies in 63 healthy volunteers.[4] They were not designed to test a clinical endpoint. The third analyzed a subset of the second cohort, not an independent third group.[5][4] None of the three published studies included anyone with a disease or condition.[4] One interventional trial for the DAC form is on the US and EU registers, recorded as terminated.[7][8] An earlier study in healthy volunteers reported no serious adverse reactions.[3] A registered trial was later stopped by its sponsor after a participant died; no peer-reviewed account exists, and causality was never adjudicated.[9][4][8]

Neither compound holds an approval in the jurisdictions FDA checked. FDA's 2024 review found no approved product containing any form of CJC-1295 in the United States, the European Union or 12 other countries.[4]

The DAC-free peptide is sold as CJC-1295 (No DAC) and also as Modified GRF(1-29), which states the construction more plainly. A widely circulated CAS number for the conjugate resolves instead to that DAC-free peptide, so an identifier check can point at the other molecule.

Neither molecule contains sulfur, so no disulfide chemistry applies to either. The bond attaching the group on CJC-1295 with DAC can hydrolyze, which leaves two separate species, and the DAC-free peptide carries no such bond.

Have CJC-1295 (No DAC) and CJC-1295 with DAC been compared directly?

No direct comparison was found in a PubMed search run in October 2026.[6] That search covers PubMed only.

Read more on each compound

Frequently Asked Questions

Is CJC-1295 (No DAC) the same as CJC-1295 with DAC?+

CJC-1295 (No DAC) is not the same molecule as CJC-1295 with DAC. CJC-1295 with DAC is a chemically modified form of it, carrying an added group that binds covalently to albumin. Jette and colleagues identified that conjugate as CJC-1295.

Does research on CJC-1295 with DAC apply to CJC-1295 (No DAC)?+

In the literature reviewed for CJC-1295 with DAC, every figure was obtained with the DAC form alone, and CJC-1295 (No DAC) is essentially uncharacterized in humans. In the literature reviewed for CJC-1295 (No DAC), the pharmacokinetic findings were generated with the DAC form as well.

References

  1. 1
    Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005 Jul;146(7):3052-8. doi:10.1210/en.2004-1286. PMID 15817669.
  2. 2
    Dominikowski A, et al. Front Endocrinol (Lausanne) 2026. PMID 42395176. DOI 10.3389/fendo.2026.1822475. Narrative review.
  3. 3
    Teichman SL, et al. J Clin Endocrinol Metab 2006. PMID 16352683. DOI 10.1210/jc.2005-1536. Human.
  4. 4
    US Food and Drug Administration, Center for Drug Evaluation and Research. Briefing document, 4 December 2024. Regulatory document, not peer-reviewed. fda.gov
  5. 5
    Sackmann-Sala L, et al. Growth Horm IGF Res 2009. PMID 19386527. DOI 10.1016/j.ghir.2009.03.001. Human.
  6. 6

    PubMed search, 3 October 2026 (records to 2 October 2026)

    3 records; none was a direct comparison of the two compounds.

    Exact query (NCBI E-utilities): ("CJC-1295"[tiab] OR "CJC 1295"[tiab] OR "CJC1295"[tiab] OR "drug affinity complex"[tiab] OR "albumin bioconjugate"[tiab] OR "albumin bioconjugates"[tiab]) AND ("modified GRF"[tiab] OR "mod GRF"[tiab] OR "modGRF"[tiab] OR "without DAC"[tiab] OR "no DAC"[tiab] OR "DAC-free"[tiab] OR "non-DAC"[tiab] OR "GRF(1-29)"[tiab] OR "GRF 1-29"[tiab] OR "GRF1-29"[tiab] OR "GHRH(1-29)"[tiab] OR "tetrasubstituted"[tiab]) AND ("1800/01/01"[edat] : "2026/10/02"[edat])

    View this search on PubMed
  7. 7
    NCT00267527, ClinicalTrials.gov registry record, last updated 12 October 2006. Not independently verified.
  8. 8
    ClinicalTrials.gov and EU Clinical Trials Register searches for CJC-1295, re-run 27 August 2026. Covers the US and EU registers only.
  9. 9
    Bernard EJ. Trade press report, 31 July 2006. Not peer-reviewed; its account of the death is explicitly anecdotal.
Dr. Martina Rossi, PhD

Reviewed for scientific accuracy

Dr. Martina Rossi, PhD

PhD, Université Grenoble Alpes · Scientific Contributor and Reviewer

Dr. Rossi's doctoral research at Université Grenoble Alpes examined the vascular functions of bone morphogenetic proteins. Her peer-reviewed work spans cell and molecular biology, vascular biology, and gene therapy, in journals including Cardiovascular Research, Scientific Reports, and Brain Sciences. She reviews Pure Peptides' product, reference, and research pages for scientific accuracy against the sources they cite.

Reviewed ORCIDGoogle ScholarTeam profile →
Comparison

CJC-1295 (No DAC) vs IGF-1 LR3

CJC-1295 (No DAC), a 29-residue peptide, and IGF-1 LR3, an 83-residue protein, are different molecules from different parents.

Read Comparison
Comparison

CJC-1295 (No DAC) vs Ipamorelin

CJC-1295 (No DAC) is a synthetic peptide built on human GHRH's first 29 residues; Ipamorelin is a synthetic five-residue peptide.

Read Comparison
Comparison

CJC-1295 (No DAC) vs Sermorelin

CJC-1295 (No DAC) is human GHRH's first 29 residues with four substitutions; Sermorelin is the unmodified fragment.

Read Comparison